Drug intelligence / Profile preview

all-trans retinoic acid + cisplatin + paclitaxel

Development stage: Unknown
Lead developer: Instituto Nacional de Cancerologia de Mexico
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of all-trans retinoic acid (ATRA), cisplatin, and paclitaxel. ATRA is a vitamin A derivative that promotes cell differentiation and has anti-cancer properties. Cisplatin is a platinum-based chemotherapy that damages DNA, while paclitaxel is a taxane that stabilizes microtubules. This combination has shown synergistic effects in treating advanced non-small cell lung cancer, with ATRA potentially preventing chemotherapy-related tumor-initiating cell enrichment and sensitizing cancer stem cells to cisplatin treatment.

Targets

MicrotubuleRAR (Retinoic acid receptor)

Beyond the preview

Go deeper on all-trans retinoic acid + cisplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on all-trans retinoic acid + cisplatin + paclitaxel.

Explore the full profile